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Introduction: Intravenous aminoglycoside therapy (IVA) is an established treat-
ment for pseudomonas in CF and is associated with irreversible ototoxicity. The
prevalence of ototoxicity in CF is reported as 0−6% in children. The UKCF Trust
and the European Consensus Committee for Antibiotic Therapy in CF do not give
guidance for screening or monitoring hearing and there is little literature available
on this subject. There is a genetic predisposition to aminoglycoside ototoxicity
associated with the mitochondrial gene A1555G. Since 2002 we have included
hearing assessment (HA) at annual review and screened all patients for A1555G.
Aim: To asses the prevalence of hearing loss in our clinic and evaluate our
HA programme.
Method: Retrospective case note analysis 2002–2009 of HA, gene result, IVA use
and aminoglycoside blood levels.
Results: Pure tone audiometry and/or distortion-product otoacoustic emissions
performed on 76 patients, age 1−17 years, 49 received IVA. Severe sensorineural
hearing loss for high frequency sounds (SNHL) identiﬁed in 1 patient and 4 had
mild SNHL. The patient with severe SNHL had one high blood level of tobramycin
recorded. No relationship between cumulative exposure and hearing loss was
identiﬁed. No hearing deﬁcit was found in patients not exposed to IVA. No patients
have the A1555G mutation.
Conclusion: We have adhered to our HA programme and have identiﬁed 5/76
(6.6%) patients with hearing loss all of whom have had IVA. From 2010 patients
with no genetic predisposition to aminoglycoside ototoxicity and no IVA will have
HA at diagnosis and at 5 and 11 years. The annual HA will continue for patients
who have had intravenous aminoglycoside.
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Background: Antibiotic therapy is essential for cystic ﬁbrosis (CF) survival and
often utilises aminoglycosides (AG). This subjects patients to risk of renal injury.
Aim: To measure glomerular ﬁltration rate (GFR) in pediatric CF patients exposed
to AG, and compare to results obtained using a current pediatric estimating equation
for GFR.
Method: GFR was measured by 2-point 99mTc-DTPA (nGFR) in patients receiving
AG. lifetime exposure to AG (< or > 1 week) was determined. Hyperﬁltration
was deﬁned as nGFR> 150ml/min/1.73m2. Age at time of nGFR was 10.3±4.9
(range 2–18.5) years. Estimated GFR (eGFR) was calculated from the 2009 updated
Schwartz equation: 41.3×(Ht/Scr) [Height (Ht: m); Serum Creatinine (Scr: mg/dl)].
Results: A total of 63 patients received AG. Table 1 shows results of nGFR and
eGFR. 1 patient had nGFR< 90; 26% of AG naive patients and 23% who had
received >1 week of AG showed hyperﬁltration. Unlike all other populations, the
eGFR consistently predicted a lower GFR.
Table 1
Aminoglycoside
exposure
GFR,
mean(SD)
Hyperﬁltration,
>150ml/min/1.73m2
Renal impairment, nGFR
<90ml/min/1.73m2
nGFR eGFR nGFR eGFR nGFR eGFR
<1 week (n = 19) 134(26) 117(27) 26% 13% 5% 19%
>1 week (n = 44) 140(23) 121(33) 23% 19% 0% 14%
All patients
(n = 63)
138(24) 120(31) 24% 17% 2% 15%
Summary: While speculative, we believe this hyperﬁltration is real. This may delay
clinical recognition of renal impairment and potential early intervention until late in
the CF course. The consequence of this will inﬂuence lung transplant suitability and
morbidity & mortality. The eGFR appeared to underestimate GFR, this suggests
that the current eGFR formulae developed in the renal disease population may not
be as accurate for CF patients.
